News & Updates
Showing Multidisciplinary articles
Showing
Skipping meal tied to increased fat deposition in type 2 diabetes
Among patients with type 2 diabetes (T2D), those who eat two meals per day exhibit higher greater intrapancreatic fat deposition than those who consume three meals per day, a study has found.
Skipping meal tied to increased fat deposition in type 2 diabetes
15 Oct 2022
Skin type factors in dupilumab efficacy in atopic dermatitis
The use of dupilumab in the treatment of atopic dermatitis appears to benefit patients who have dark skin types more than those who have light skin types, as shown in a study.
Skin type factors in dupilumab efficacy in atopic dermatitis
15 Oct 2022
Sigmoidoscopy screening offers 15-year benefit in CRC incidence, mortality
Sigmoidoscopy screening provides a significant and sustained effect on colorectal cancer (CRC) incidence and mortality for 15 years, according to a pooled analysis of randomized trials.
Sigmoidoscopy screening offers 15-year benefit in CRC incidence, mortality
15 Oct 2022
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
First-line treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP1) receptor agonists improves outcomes in patients with type 2 diabetes (T2D), but to be cost-effective, the prices of these drugs must drop by at least 70 percent, suggests a study.
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
15 Oct 2022
Pemetrexed-based chemo boosts survival in NSCLC
As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.
Pemetrexed-based chemo boosts survival in NSCLC
15 Oct 2022
Pre-DAA IL-1β can predict HBV reactivation in HCV
Among hepatitis C virus (HCV) patients with resolved hepatitis B virus (HBV) infections, levels of interleukin (IL)-1β before the initiation of direct-acting antiviral (DAA) treatment may help predict HBV reactivation, reports a recent study.